One day, two AstraZeneca deals

Share this article:

AstraZeneca expanded the footprint of its biologics arm MedImmune on Tuesday with two announcements: first, that it purchased Spirogen, a private biotech, for $440 million, and second that it joined up with ADC Therapeutics to develop two antibody drug conjugate (ADC) programs.

The ADC deal involves trading $20 million for an equity investment in ADC along with milestone payments. The linkage between the two deals is that Auven Therapeutics is the majority stakeholder in both ADC and Spirogen.

The deals follow AZ's August acquisition of Amplimmune as part of an expansive oncology push.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.